Bio-Rad and the University of Chicago Win Patent Infringement Case Against 10X Genomics

A Federal District Court jury found that 10X Genomics willfully infringed three United States patents owned by the University of Chicago and exclusively licensed to Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products. In awarding Bio-Rad USD 23.9 million in damages, the jury unanimously found that all Single Cell and Linked-Read genomics products sold by 10X Genomics willfully infringed the patents owned by the University of Chicago and licensed to Bio-Rad. “We are obviously pleased with the outcome of the case,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer. “Bio-Rad remains committed to growing and protecting its portfolio of patents in the droplet microfluidics space and to delivering differentiated genomics technologies that enable world class research.” In a separate earlier action before the International Trade Commission, an administrative law judge made an initial determination that certain microfluidic devices used by 10X in its products infringe patent rights owned by Bio-Rad. – Medical Buyer Bureau